Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 14
Healthy volunteers: no

Brief summary:
A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.

Detailed description:

Arms:
arm 1: MK8245 arm 2: MK8245 arm 3: Placebo

Interventions: intervention 1: MK8245 5 mg (twice a day) b.i.d. intervention 2: MK8245 50 mg b.i.d. intervention 3: Placebo
Intervention descriptions: intervention 1: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.

Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening. intervention 2: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.

Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening. intervention 3: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.

Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening.

Protocol document: